Commitments (Details Narrative) - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Sep. 12, 2016 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| Matinas BioPharma Nanotechnologies, Inc. [Member] | |||
| Loss Contingencies [Line Items] | |||
| Business acquisition equity interest issuable, description | Pursuant to the terms of the merger agreement with Aquarius Biotechnologies, Inc., the Company may be required to issue up to an additional 3,000,000 shares of our common stock upon the achievement of certain milestones. The milestone consideration consists of (i) 1,500,000 shares issuable upon the dosing of the first patient in a phase III trial sponsored by us for a product utilizing Aquarius’ proprietary LNC platform delivery technology and (ii) 1,500,000 shares issuable upon FDA approval of the first NDA submitted by us for a product utilizing Aquarius’ proprietary LNC platform delivery technology. The Company concluded that the contingent share issuance represented equity settled contingent consideration and have recorded the amounts to equity since inception. None of these milestones have been reached, and accordingly, as of December 31, 2020 no additional shares have been issued. | ||
| Number of shares issued for aquisition | 0 | ||
| Series A Preferred Stock [Member] | |||
| Loss Contingencies [Line Items] | |||
| Royalty payment rights, description | the Company is required to pay to the holders of the Series A Preferred Stock, subject to certain vesting requirements, in the aggregate, a royalty (the “Royalty Payment Rights”) equal to (i) 4.5% of Net Sales (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $25 million per calendar year, and (ii) 7.5% of Licensing Proceeds (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $10 million per calendar year. | ||
| Royalty payment rights expire description | The Royalty Payment Rights will expire when the patents covering the applicable product expire, which is currently expected to be in 2033 | ||
| Series A Preferred Stock [Member] | Maximum [Member] | |||
| Loss Contingencies [Line Items] | |||
| Accrued royalties | $ 35 | ||
| Series A Preferred Stock [Member] | Maximum [Member] | 4.5% of Net Sales [Member] | |||
| Loss Contingencies [Line Items] | |||
| Accrued royalties | 25 | ||
| Series A Preferred Stock [Member] | Maximum [Member] | 7.5% of Net Sales [Member] | |||
| Loss Contingencies [Line Items] | |||
| Accrued royalties | $ 10 | ||